Xenobiotic-metabolizing enzymes in human lung

Area of Science:

• Pulmonary Toxicology
• Pharmacology
• Biochemistry

Background:

• The human lung is a primary target for inhaled environmental toxicants and carcinogens.
• Xenobiotic metabolism in the lung is critical for understanding lung disease pathogenesis, including lung cancer and COPD.
• Enzymatic activation and inactivation of xenobiotics influence individual susceptibility to lung diseases.

Purpose of the Study:

• To review the major xenobiotic-metabolizing enzymes in the human lung.
• To detail Phase I and Phase II enzymes expressed in lung tissue.
• To discuss the roles of these enzymes and their genetic polymorphisms in lung disease risk.

Main Methods:

• Literature review of studies on xenobiotic metabolizing enzymes in human and animal lung tissues.
• Identification and characterization of Phase I enzymes (e.g., Cytochrome P450s, epoxide hydrolases, flavin monooxygenases).
• Identification and characterization of Phase II enzymes (e.g., conjugation enzymes, transferases).

Main Results:

• The human lung expresses various xenobiotic metabolizing enzymes, including Cytochrome P450s (CYPs), epoxide hydrolases, and flavin monooxygenases (Phase I), as well as conjugation enzymes (Phase II).
• Specific CYPs like CYP1A1, 1B1, 2A13, 2F1, 2S1, 4B1, 2E1, and 3A5 are preferentially expressed in the lung.
• Distinctive differences exist in lung xenobiotic metabolism compared to other organs like the liver.

Conclusions:

• The human lung possesses a significant capacity for xenobiotic metabolism through a diverse array of Phase I and Phase II enzymes.
• Preferential expression of certain enzymes in the lung highlights its unique role in processing inhaled compounds.
• Genetic polymorphisms in these lung metabolizing enzymes may contribute to interindividual differences in susceptibility to lung diseases.